- PR Newswire•6 days ago
AUSTIN, Texas, Feb. 14, 2017 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company, announced today that investors, including several Vermillion directors and members of management as well as certain significant stockholders, have agreed to purchase approximately $5.6 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion's common stock in a private placement. Under the terms of the private placement, Vermillion has agreed to sell an aggregate of 3,747,125 shares of its common stock at the price of $1.40 per share, the closing price quoted on NASDAQ on February 10, 2017.
- PR Newswire•last month
AUSTIN, Texas , Jan. 9, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company, today announced that the company and its wholly owned subsidiary, ASPiRA Labs, have received ...
- PR Newswire•2 months agoVermillion and ASPiRA LABS Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) and ASPiRA LABS, a Vermillion company, today announced the receipt of an FDA Clarification Letter regarding OVA1 (MIA) and Overa (MIA2G). ...
VRML : Summary for Vermillion, Inc. - Yahoo Finance
Vermillion, Inc. (VRML)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.75 x 100|
|Ask||1.80 x 200|
|Day's Range||1.50 - 1.75|
|52 Week Range||0.76 - 1.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|